# Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

> **NCT05126563** · PHASE2 · COMPLETED · sponsor: **Hope Biosciences Research Foundation** · enrollment: 79 (actual)

## Conditions studied

- Post COVID-19 Syndrome

## Interventions

- **BIOLOGICAL:** HB-adMSCs (allogeneic)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05126563
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126563, "Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05126563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*